Angiotensin II receptors

The Paal-Knorr furan synthesis can also be used to prepare 2,5-arylalkylfurans, as illustrated in the following example. Salimbeni produced furan 29 from dione 28 and subsequently used the furan as an intermediate for the production of angiotensin II receptor antagonists. ... 

Alkoxy-3- 4-[2-(5-tetrazolyl)phenyl]phenylmethyl -4/f-pyrido[l,2-a]py-rimidin-4-ones 417 exhibited potential angiotensin II receptor antagonistic activities (94BMCL183). 

Kuznetsova T, Staessen JA, Thijs L et al (2004) European Project On Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 110 2644-2650... 

Angiotensin II receptor antagonists—for example, irbesartan (Avapro), losartan (Cozaar), and valsar-tan (Diovan)... 

Antihypertensive drugp are contraindicated in patients with known hypersensitivity to the individual dm. When an antihypertensive is administered by a trans-derrnal system (eg, clonidine), the system is contraindicated if the patient is allergic to any component of the adhesive layer of the transdermal system. Use of the angiotensin II receptor antagonists during the second and third trimester of pregnancy is contraindicated... 

The hypotensive effects of most antihypertensive dru are increased when administered with diuretics and other antihypertensives. Many dnigp can interact with the antihypertensive drugs and decrease their effectiveness (eg, antidepressants, monoamine oxidase inhibitors, antihistamines, and sympathomimetic bronchodilators). When the ACE inhibitors are administered with the NSAIDs, their antihypertensive effect may be decreased. Absorption of the ACE inhibitors may be decreased when administered with the antacids. Administration of potassium-sparing diuretics or potassium supplements concurrently with the ACE inhibitors may cause hyperkalemia. When the angiotensin II receptor agonists are administered with... 

Berellini G, Cruciani G, Mannhold R. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide ATi, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem 2005 48 4389-99. 

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers decrease protein excretion and are the drugs of choice for hypertension in patients with CKD. 

Medications can increase the risk of hyperkalemia in patients with CKD, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, used for the treatment of proteinuria and hypertension. Potassium-sparing diuretics, used for the treatment of edema and chronic heart failure, can also exacerbate the development of hyperkalemia, and should be used with caution in patients with stage 3 CKD or higher. 

ACE-I, angiotensin-converting enzyme inhibitor ADH, antidiuretic hormone (or vasopressin) ARB, angiotensin II receptor blocker, MESNA, sodium 2-mercaptoethanesulfonate TCA, tricyclic antidepressant Ul, urinary incontinence SUI, stress urinary incontinence UUI, urge urinary incontinence. 

Electrostatic potential of a new angiotensin II receptor antagonist from X-ray diffraction and ab initio calculations... 

Salimbeni, A., Canevotti, R., Paleari, E, Poma, D., Caliari, S., Fici, E, Cirillo, R., Renzetti, A.R., Subissi, A., Belvisi, L., Bravi, G., Scolastico, C. and Giachetti, A. (1995) N-3-substituted pyrim-idinones as potent, orally active, AT, selective angiotensin II receptor antagonists, J. Med. Chem., 38, 4806 1820. 

Destro, R. and Soave, R. (1995) A new non-peptide angiotensin II receptor antagonist, Acta Crystallogr., C51, 1383-1385. 

Angiotensin II receptor antagonists. These agents promote vasodilation (1 TPR), increase sodium and water excretion, and, therefore, decrease plasma volume (1 CO). 

Compound 686 (PNU-97018) is an orally active nonpeptide angiotensin II receptor antagonist without any agonistic activity that has an insurmountably high antihypertensive effect <2002CPB1022, 1995JEP1042, 1995MI880>. 

---